Safety, immunogenicity, and efficacy of an mRNA COVID-19 vaccine (RQ3013) given as the fourth booster following three doses of inactivated vaccines: a double-blinded, randomised, controlled, phase 3b trial-Reference-Cited by-同舟云学术

Safety, immunogenicity, and efficacy of an mRNA COVID-19 vaccine (RQ3013) given as the fourth booster following three doses of inactivated vaccines: a double-blinded, randomised, controlled, phase 3b trial

Published:2023-10 Issue: Volume:64 Page:102231
ISSN:2589-5370
Container-title:eClinicalMedicine
language:en
Short-container-title:eClinicalMedicine

Author:

Liu Xiaoqiang,Sun Zhonghan^ORCID,Wang Zhongfang,Chen Jingjing,Wu Qianhui,Zheng Yan,Yang Xiaoyun,Mo Luhui,Yan Xuemei,Li Wei,Zou Yanxiang,Song Huiling^ORCID,Qian Feng,Lu Jing,Zhou Hui,Wang Yaping,Xiang Zuoyun,Yu Hongjie,Lin Jinzhong,Yuan Lin,Zheng Yan^ORCID

Publisher

Elsevier BV

Subject

General Medicine

Reference30 articles.

1. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape;Tregoning;Nat Rev Immunol,2021

2. The effects of the COVID-19 pandemic on community respiratory virus activity;Chow;Nat Rev Microbiol,2023

3. Efficacy of a fourth dose of Covid-19 mRNA vaccine against Omicron;Regev-Yochay;N Engl J Med,2022

4. Determinants of COVID-19 vaccination status and hesitancy among older adults in China;Wang;Nat Med,2023

5. Considerations in boosting COVID-19 vaccine immune responses;Krause;Lancet,2021

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Development of Epitope-Based Recombinant Protein Vaccines against SARS-CoV-2;The AAPS Journal;2024-08-13

2. Efficacy, immunogenicity, and safety of a monovalent mRNA vaccine, ABO1020, in adults: A randomized, double-blind, placebo-controlled, phase 3 trial;Med;2024-07

3. COVID-19 vaccination and major cardiovascular and haematological adverse events in Abu Dhabi: retrospective cohort study;Nature Communications;2024-06-28

4. Preclinical evaluation of RQ3013, a broad-spectrum mRNA vaccine against SARS-CoV-2 variants;Science Bulletin;2023-12